NCT01467934

FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging

FeverText: Assessing Fever Rates After Influenza and Pneumococcal Vaccination During the 2011-12 Influenza Season Using Text Messaging

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 530 (actual)
• Sponsor: Columbia University · Academic / Other
• Sex: All
• Age: 6 Months – 23 Months
• Healthy volunteers: Not accepted

Summary

In this study, the investigators will prospectively assess fever rates and other associated vaccine adverse events in 6-23 month old patients during days 0-7 after administration of trivalent inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine (PCV13) concomitantly compared to those who receive trivalent inactivated influenza vaccine (TIV) or 13-valent pneumococcal conjugate vaccine (PCV13) administered non-concomitantly. The investigators hypothesize that fever rates will be significantly higher during the 0-1 days after vaccination when inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine (PCV13) are given concomitantly than when TIV or PCV13 is administered non-concomitantly.

Conditions

• Fever

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-04-01
• Completion: 2012-06-01
• First posted: 2011-11-09
• Last updated: 2014-07-21
• Results posted: 2014-07-21

Locations

2 sites across 1 country: United States